Cargando…
Ten Years and Counting: Moving Leucine-Rich Repeat Kinase 2 Inhibitors to the Clinic
The burden that Parkinson's disease (PD) exacts on the population continues to increase year after year. Though refinement of symptomatic treatments continues at a reasonable pace, no accepted therapies are available to slow or prevent disease progression. The leucine-rich repeat kinase 2 (LRRK...
Autor principal: | West, Andrew B |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BlackWell Publishing Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4318704/ https://www.ncbi.nlm.nih.gov/pubmed/25448543 http://dx.doi.org/10.1002/mds.26075 |
Ejemplares similares
-
Leucine Rich Repeat Kinase 2 and Innate Immunity
por: Ahmadi Rastegar, Diba, et al.
Publicado: (2020) -
Leucine-rich repeat kinase 2 at a glance
por: Zhu, Christiane, et al.
Publicado: (2023) -
An extracellular network of Arabidopsis leucine-rich repeat receptor kinases
por: Smakowska-Luzan, Elwira, et al.
Publicado: (2018) -
Inhibitors of Leucine Rich Repeat Kinase 2 (LRRK2) Protect Against LRRK2-Models of Parkinson’s Disease
por: Lee, Byoung Dae, et al.
Publicado: (2010) -
Leucine-Rich repeat receptor kinases are sporadically distributed in eukaryotic genomes
por: Diévart, Anne, et al.
Publicado: (2011)